BrightPath Biotherapeutics

4594.TTSE GROWTHPharmaceutical
Filed as BrightPath Biotherapeutics Co., Ltd (2022-06–2026-06)
Financials · Consolidated
Fiscal year ended2018-032017-032016-03
Revenue¥354m¥530m—
Operating income−¥1.6bn−¥1.1bn—
Ordinary income−¥1.6bn−¥1.1bn—
Net income (owners)−¥1.6bn−¥1.1bn—
Total assets¥7.2bn¥5.4bn—
Net assets / equity¥7.0bn¥5.2bn¥2.7bn
Operating cash flow−¥1.6bn−¥1.1bn—
EPS (basic)¥-41.25¥-32.74—

From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 10
PeriodFormFiledFigures
2025-04-01 → 2026-03-31Annual2026-06-25108 figures · EDINET
2024-04-01 → 2025-03-31Annual2025-06-19108 figures · EDINET
2023-04-01 → 2024-03-31Annual2024-06-21108 figures · EDINET
2022-04-01 → 2023-03-31Annual2023-06-22108 figures · EDINET
2017-04-01 → 2018-03-31AnnualAmended2022-12-19152 figures · EDINET
2018-04-01 → 2019-03-31AnnualAmended2022-12-19120 figures · EDINET
2019-04-01 → 2020-03-31AnnualAmended2022-12-19126 figures · EDINET
2020-04-01 → 2021-03-31AnnualAmended2022-12-19126 figures · EDINET
2021-04-01 → 2022-03-31AnnualAmended2022-12-19117 figures · EDINET
2021-04-01 → 2022-03-31Annual2022-06-23117 figures · EDINET

21 more reports are still being processed.